Drugs & Targets FDA approves Breyanzi for relapsed or refractory mantle cell lymphoma June 14, 2024Vol.50 No.24
Drugs & Targets FDA grants accelerated approval to Augtyro for NTRK gene fusion-positive solid tumors June 14, 2024Vol.50 No.24
Drugs & Targets FDA approves imetelstat for low- to intermediate-1 risk MDS with transfusion-dependent anemia June 07, 2024Vol.50 No.23
Drugs & Targets FDA grants accelerated approval to selpercatinib for pediatric RET-altered metastatic thyroid cancer or solid tumors May 31, 2024Vol.50 No.22
Drugs & Targets FDA acknowledges BLA resubmission for Zolbetuximab for HER2- gastric or GEJ adenocarcinoma with CLDN18.2-positive tumors May 31, 2024Vol.50 No.22
Drugs & Targets European Commission approves Opdivo combination for unresectable or metastatic UC May 31, 2024Vol.50 No.22
Drugs & Targets NHS England will wait to consider NHS rollout of Galleri multi-cancer early detection test May 31, 2024Vol.50 No.22
Drugs & Targets Estonia to develop personalized CAR T-cell therapy for blood cancer patients May 31, 2024Vol.50 No.22
Drugs & Targets Secarna, Orbit collaborate to develop peptide-conjugated targeted ASO therapeutics May 31, 2024Vol.50 No.22
